Small and medium-sized enterprises: driving innovation in medicines
Supporting developers of life-changing medicines
Micro, small and medium-sized enterprises (SMEs) are a motor of innovation in the European Union (EU). Between 2010 and 2012, more than one in four new innovative medicines recommended for marketing authorisation in the EU originated from SMEs, as shown in an analysis published in January 2014.
Innovative medicines have the potential to bring significant benefits to patients and address unmet medical needs. As they act in a different way to existing treatments or target patients who can benefit most from the therapy, these medicines offer new avenues to treat patients differently while maximising the benefits and reducing the risks.
Recently, the first medicine authorised for the treatment of the life-threatening disease Duchenne muscular dystrophy (Translarna) originated from an SME. This medicine displays a completely new mode of action that directly targets the cause of the disease. Another recent example is the first non-surgical treatment option (Jetrea) for adults with vitreomacular traction, an eye condition which can cause severe visual disturbance. This new medicine spares patients from having to stay in a ‘head-down’ position for days to enhance the success rate of the surgical procedure.
SMEs are also highly active in the development of advanced therapies, innovative medicines that are based on gene, cell or tissue engineering, as well as in the development of medicines for rare diseases. In these two categories of medicines that can clearly improve patient health, SMEs account for about half of all new medicines under development.
“Supporting the actors in the pharmaceutical industry who contribute to enhancing public health by focusing on innovation is a priority for the European Medicines Agency,” explains Melanie Carr, Head of EMA’s Corporate Stakeholder Department. “Our dedicated structure to support smaller companies as well as our ongoing work to reinforce engagement with the academic world, are both intended to further support the translation of innovation into successful developments in the interest of patients.”
The Agency’s SME Office provides active regulatory, financial and administrative support to registered SMEs in the development of their medicines. Almost one in two SMEs registered with the Agency has less that 10 staff members and 12% originate from academia.
In addition, the Agency supports innovation at very early stages of a medicine’s development through its Innovation Task Force. This taskforce provides a forum for early dialogue with applicants. During free-of-charge briefings, medicines developers can discuss their initial research findings with the Agency’s experts and proactively identify any scientific, legal and regulatory issues and opportunities.
Over the past five years, almost one third of all the taskforce’s briefings have been conducted with SMEs. Two out of three meetings with SMEs concerned either cell-based, gene-based or tissue engineering-based therapies. New medicines for the treatment of cancer represent the largest category.
While there is still a long way to go before these medicines can potentially reach patients, early dialogue between medicines developers and regulatory authorities has proved to increase the chances of obtaining a marketing authorisation in a timely manner, thereby accelerating patients’ access to new medicines.
The EMA supports European SME Week, which is taking place from 29 September to 5 October 2014. European SME Week promotes enterprise across Europe by supporting the work of SMEs. It is co-ordinated by the European Commission.
How useful is this page?
Average rating:Based on 0 ratings
Add your rating:
- See all ratings
0 ratings0 ratings0 ratings0 ratings0 ratings
- European SME week
- Enterprise Europe Network
- Regulatory watch: Where do new medicines originate from in the EU?
- Clinical Development of Advanced Therapy Medicinal Products in Europe: Evidence That Regulators Must Be Proactive
- Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency